# Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With COPD With Poor MDI Technique.

> **NCT00267917** · PHASE4 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 13 (—)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive
- Asthma

## Interventions

- **DEVICE:** Berodual Respimat
- **DEVICE:** Berodual HFA-MDI

## Key facts

- **NCT ID:** NCT00267917
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01-17
- **Primary completion:** 2006-02-27
- **Final completion:** 2006-02-27
- **Target enrollment:** 13 (—)
- **Last updated:** 2023-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00267917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00267917, "Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With COPD With Poor MDI Technique.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00267917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*